Mobile Digital Health Platforms Use in TAVR

By Staff Writer

February 2, 2024

Transforming Patient Outcomes in Aortic Valve Replacement

Aortic stenosis (AS) is a condition that affects around 12.4% of the global population and seen most prevalent in the elderly with an estimated 10% of individuals over the age of 80 being affected. Traditionally, surgical aortic valve replacement (SAVR) was the only treatment method as there is no medicine to treat this condition. However, transcatheter aortic valve replacement (TAVR) is becoming increasingly popular among healthcare practitioners and patients due to its less invasive nature and similar clinical outcomes. This also allows for the option of valve replacement in severe AS.

Mobile Digital Health Platforms: The Future of Patient Education

With the rise of smartphones, digital health technology has become a powerful tool in patient education and monitoring. Mobile applications are now being used to collect patient data, facilitate communication between patients and providers, and most importantly, improve patient outcomes. This has been proven to be successful in the management of diseases such as diabetes and chronic heart disease. Mobile apps for Gastroenterological and orthopaedic surgery reduce follow-up visits and monitor postoperative wounds. Prostate-, and lung cancer, and C-section postoperative outcomes can also be collected via mobile apps.

The Efficacy of Digital Health Platforms: A Case Study

A recent study focused on the effectiveness of a mobile digital health platform, ManageMySurgery (MMS). MMS is a mobile app that supports patients during interventional procedures. This app contains links about surgery, care team communication, and duties to prepare patients for their treatments. It also serves as a reminder for checking into appointments, confirming preoperative instructions, and completing pre- and post-op surveys. The results were impressive, with significant reductions in emergency room visits, hospital readmissions, and complications among patients using the app.

Understanding the Mechanism of Benefit

This digital health application stands as one of the first for cardiac surgery shown to improve patient outcomes through objective measurements. While it’s not possible to prove direct causality, the study’s results suggest that digital health tools can significantly improve patient outcomes including reduced rehospitalisation and emergency room visits. These apps serve as partners in patients’ journeys, reminding them of actions they need to take before and after surgery. This ensures improved outcomes and a better quality of life.

Limitations and Future Directions

Despite the promising results, the study was not without limitations, including the potential for selection bias and the fact that it focused solely on TAVR patients. Future studies could expand the focus to include a wider variety of cardiothoracic procedures and explore the potential benefits of integrating the app with electronic medical records.

The Future of Digital Health in Healthcare

This study represents a significant step forward in understanding the potential of digital health platforms in improving patient outcomes. By engaging patients throughout every step of their surgical procedure, digital health tools can help improve individual patient wellbeing. Resulting in reduced the workload on healthcare providers, and assisting with alleviating the overall burden on healthcare resources.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.